SENS to Pop on Stifel $2 price target and Insider Buying
========================
Senseonics Holdings, Inc. (SENS)
Alert Price: $1.23
Float: 149.41
Chart Analysis
Investor Presentation
Price Target: $2.00
(Stifel)
Company Website | Recent News
========================
Members,
Act Fast, and get Senseonics Holdings, Inc. (SENS) on your screen and ready to trade.
The last time we brought SENS to your attention, shares ran up over +30% in one session, and over +234% for the year!
Shares on SENS have pulled back considerably since then, but we are predicting another epic bull run for this NYSE listed company.
SENS Is Showing Us All The Signs Of A Company That Is Ready To Reverse Hard Off Its Lows And Start A Big Time Bull Rally:
Heavy Insider Buying
Analyst Upgrades
Strong Revenue Growth
Bullish Trending Chart
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' CGM systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. Starting this fall, the system will be used to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements will still be required for calibration twice per day, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider.
Company Highlights
Disruptive, Highly-Innovative Technology in a Fast-Growing CGM Market with a 1 Significant Unmet Need
Clinically Proven CGM System Providing Enhanced Patient Experience and 2 Clinical Outcomes
Access to Key Global Markets with Increasing Coverage and Successful 3 Commercialization in Europe and the US
4 Robust Product Strategy and Deep Pipeline to Support Long-Term Growth
Stifel Starts Senseonics Holdings (SENS) at Buy. Predicts Move Of +62% From Here
Stifel analyst Mathew Blackman initiates coverage on Senseonics Holdings (NYSE: SENS) with a Buy rating and a price target of $2.00.
The analyst comments "The SENS story is in the earliest of innings and not surprisingly, the company faces a number of commercialization challenges, most notably garnering broad reimbursement and high cash burn. Nonetheless, our thesis is straightforward: (1) we believe CGM is the most critical piece of the diabetes technology eco-system; (2) SENS' implantable sensor is differentiated and can appeal to patients averse to frequent sensor changes and other quality-of-life headwinds associated with fingersticks and current CGM systems; and (3) assuming a $5B+ CGM opportunity today (intensive-insulin), even if the ultimate Eversense patient cohort only appeals to 5% of the market, SENS revenue base should approximate $200M-300M, significantly higher than current valuation contemplates."
SENS Announces a Positive Coverage Decision for Eversense CGM From Humana
Two weeks ago, the Company announced that Humana is now providing coverage for the Eversense CGM System and insertion procedure, effective October 22, 2019. Under the Humana coverage policy patients with both type 1 diabetes and type 2 diabetes that require insulin are eligible for coverage for Eversense.
Humana is the fifth largest health insurer in the US covering 17 million patients across all 50 states, Washington DC and Puerto Rico.
“Eversense and the insertion procedure being included in the Humana CGM policy once again validates that an increasing number of payers are supporting the value our long-term CGM provides to patients with diabetes,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. “We are especially pleased that access has been included for not only for the type 1 diabetes patients but also for the type 2 patients that require insulin. We are confident that Eversense can conveniently assist all patients in managing their diabetes.”
The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. In addition to featuring the first long-term and first implantable CGM sensor, the system is also first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts when high or low glucose thresholds are crossed and can be removed, recharged and re-adhered without discarding the sensor. The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure.
Heavy Insider Buying Tells A Story Of A Grossly Undervalued Company
Over the past 12-months SENS insiders have made a total of 26-insider buys and ZERO insider sells!
President and CEO of Senseonics Holdings Inc Timothy T Goodnow bought 88,500 shares of SENS on 09/09/2019 at an average price of $1.10 a share. The total cost of this purchase was $97,350.
A large purchase like that should give potential SENS buyers a strong sense of confidence heading into the trade.
It is quite obvious that SENS management believes that the Company's stock is undervalued at these current levels.
Not that long ago, shares of SENS were trading at double than what they are now.
We agree with the analyst's estimates, and believe it's just a matter of time before SENS is trading back above $2.00
Remember...
The last time we were this bullish on SENS, shares ran up over +234%!
SENS Is Addressing An Unmet Need In A $2B Market
CGM Is The Fastest Growing Diabetes Technology Segment Globally
Eversense Addresses
Unmet Needs
Long-term: sensor lasts up to 180 days
Only needs to be switched 4x a year vs. 36x a year
Fully implantable sensor
On-body vibration alerts
Accuracy
Flexibility: removable transmitter
Safety
Adoption Strategy
Differentiation
Drive Demand from HCPs
Patients Clinical Demonstration
Patients Are Adopting Eversense Treatment At A Rapid Pace
85% Lead Increase from March 1 - June 30, 2019
102% Prescription Increase from March 1- June 30, 2019
310% New Patient Shipment Increase from March 1 - June 30, 2019
550 HCPs Prescribed as of June 30, 2019
SENS Chart Forming A Golden Cross. We Anticipate A Nice Move From Here
The golden cross is a technical chart pattern indicating the potential for a major rally.
The golden cross is a candlestick pattern that is a bullish signal in which a relatively short-term moving average crosses above a long-term moving average. The golden cross is a bullish breakout pattern formed from a crossover involving a security's short-term moving average (such as the 15-day moving average) breaking above its long-term moving average (such as the 50-day moving average) or resistance level.
Some of our biggest winners have had this exact same setup.
We've done our very own chart analysis, and see the potential for a move of over +40% from today's alert price!
The Bottom Line
SENS may be one of the most undervalued companies trading on the NYSE at the moment.
With its strong revenue growth and heavy insider buying, we are confident SENS will meet analysts $2.00 Price Target.
Traders who are looking for +100% ROI should get SENS on their screens immediately!
(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.)
Best Regards,
Past performance is not an indicator of future returns. The publishers of this report are not investment advisors and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. The publishers of this report has not received compensation to complete this marketing campaign for SENS. Never make investment decisions based on anything the publisher of this report says. This message is meant for informational and educational purposes only and does not provide investment advice. The issueres of this report placed $1,000 USD spread bet on SENS to go up, however does not own, but may acquire and then sell shares of SENS within the near future.
Senseonics Holdings, Inc. (SENS)
Alert Price: $1.23
Float: 149.41
Chart Analysis
Investor Presentation
Price Target: $2.00
(Stifel)
Company Website | Recent News
========================
Members,
Act Fast, and get Senseonics Holdings, Inc. (SENS) on your screen and ready to trade.
The last time we brought SENS to your attention, shares ran up over +30% in one session, and over +234% for the year!
Shares on SENS have pulled back considerably since then, but we are predicting another epic bull run for this NYSE listed company.
SENS Is Showing Us All The Signs Of A Company That Is Ready To Reverse Hard Off Its Lows And Start A Big Time Bull Rally:
Heavy Insider Buying
Analyst Upgrades
Strong Revenue Growth
Bullish Trending Chart
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' CGM systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. Starting this fall, the system will be used to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements will still be required for calibration twice per day, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider.
Company Highlights
Disruptive, Highly-Innovative Technology in a Fast-Growing CGM Market with a 1 Significant Unmet Need
Clinically Proven CGM System Providing Enhanced Patient Experience and 2 Clinical Outcomes
Access to Key Global Markets with Increasing Coverage and Successful 3 Commercialization in Europe and the US
4 Robust Product Strategy and Deep Pipeline to Support Long-Term Growth
Stifel Starts Senseonics Holdings (SENS) at Buy. Predicts Move Of +62% From Here
Stifel analyst Mathew Blackman initiates coverage on Senseonics Holdings (NYSE: SENS) with a Buy rating and a price target of $2.00.
The analyst comments "The SENS story is in the earliest of innings and not surprisingly, the company faces a number of commercialization challenges, most notably garnering broad reimbursement and high cash burn. Nonetheless, our thesis is straightforward: (1) we believe CGM is the most critical piece of the diabetes technology eco-system; (2) SENS' implantable sensor is differentiated and can appeal to patients averse to frequent sensor changes and other quality-of-life headwinds associated with fingersticks and current CGM systems; and (3) assuming a $5B+ CGM opportunity today (intensive-insulin), even if the ultimate Eversense patient cohort only appeals to 5% of the market, SENS revenue base should approximate $200M-300M, significantly higher than current valuation contemplates."
SENS Announces a Positive Coverage Decision for Eversense CGM From Humana
Two weeks ago, the Company announced that Humana is now providing coverage for the Eversense CGM System and insertion procedure, effective October 22, 2019. Under the Humana coverage policy patients with both type 1 diabetes and type 2 diabetes that require insulin are eligible for coverage for Eversense.
Humana is the fifth largest health insurer in the US covering 17 million patients across all 50 states, Washington DC and Puerto Rico.
“Eversense and the insertion procedure being included in the Humana CGM policy once again validates that an increasing number of payers are supporting the value our long-term CGM provides to patients with diabetes,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. “We are especially pleased that access has been included for not only for the type 1 diabetes patients but also for the type 2 patients that require insulin. We are confident that Eversense can conveniently assist all patients in managing their diabetes.”
The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. In addition to featuring the first long-term and first implantable CGM sensor, the system is also first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts when high or low glucose thresholds are crossed and can be removed, recharged and re-adhered without discarding the sensor. The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure.
Heavy Insider Buying Tells A Story Of A Grossly Undervalued Company
Over the past 12-months SENS insiders have made a total of 26-insider buys and ZERO insider sells!
President and CEO of Senseonics Holdings Inc Timothy T Goodnow bought 88,500 shares of SENS on 09/09/2019 at an average price of $1.10 a share. The total cost of this purchase was $97,350.
A large purchase like that should give potential SENS buyers a strong sense of confidence heading into the trade.
It is quite obvious that SENS management believes that the Company's stock is undervalued at these current levels.
Not that long ago, shares of SENS were trading at double than what they are now.
We agree with the analyst's estimates, and believe it's just a matter of time before SENS is trading back above $2.00
Remember...
The last time we were this bullish on SENS, shares ran up over +234%!
SENS Is Addressing An Unmet Need In A $2B Market
CGM Is The Fastest Growing Diabetes Technology Segment Globally
Eversense Addresses
Unmet Needs
Long-term: sensor lasts up to 180 days
Only needs to be switched 4x a year vs. 36x a year
Fully implantable sensor
On-body vibration alerts
Accuracy
Flexibility: removable transmitter
Safety
Adoption Strategy
Differentiation
Drive Demand from HCPs
Patients Clinical Demonstration
Patients Are Adopting Eversense Treatment At A Rapid Pace
85% Lead Increase from March 1 - June 30, 2019
102% Prescription Increase from March 1- June 30, 2019
310% New Patient Shipment Increase from March 1 - June 30, 2019
550 HCPs Prescribed as of June 30, 2019
SENS Chart Forming A Golden Cross. We Anticipate A Nice Move From Here
The golden cross is a technical chart pattern indicating the potential for a major rally.
The golden cross is a candlestick pattern that is a bullish signal in which a relatively short-term moving average crosses above a long-term moving average. The golden cross is a bullish breakout pattern formed from a crossover involving a security's short-term moving average (such as the 15-day moving average) breaking above its long-term moving average (such as the 50-day moving average) or resistance level.
Some of our biggest winners have had this exact same setup.
We've done our very own chart analysis, and see the potential for a move of over +40% from today's alert price!
The Bottom Line
SENS may be one of the most undervalued companies trading on the NYSE at the moment.
With its strong revenue growth and heavy insider buying, we are confident SENS will meet analysts $2.00 Price Target.
Traders who are looking for +100% ROI should get SENS on their screens immediately!
(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.)
Best Regards,
Past performance is not an indicator of future returns. The publishers of this report are not investment advisors and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. The publishers of this report has not received compensation to complete this marketing campaign for SENS. Never make investment decisions based on anything the publisher of this report says. This message is meant for informational and educational purposes only and does not provide investment advice. The issueres of this report placed $1,000 USD spread bet on SENS to go up, however does not own, but may acquire and then sell shares of SENS within the near future.